Clarus readies a slate of big PhIII risk-sharing bets with a new $910M fund
About 8 years ago, the crew at Clarus Ventures had a sit down with a pharma company they were looking to sell one of their portfolio biotechs to. The talks went well, the company wanted the assets. But there was a big obstacle.
The buyer they were talking to couldn’t afford to just acquire the company and fit in another late-stage drug program under its R&D budget. Those numbers couldn’t change willy nilly — no matter how good the new late-stage drug looked.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.